BillionToOne drops 6% premarket on Fuzzy Panda short report
Investing.com · · AI-summarised by FinFlash
Shares of prenatal genetic testing firm BillionToOne fell about 6% in premarket trading after short seller Fuzzy Panda Research published a report alleging questionable Medicaid billing practices. The report cites a Tennessee Medicaid inquiry, carrier screening allegedly billed alongside about 88% of prenatal tests in Michigan data, and patient cost caps of $99 to $349. Fuzzy Panda estimates curbs could cut EBITDA by about 80%. The company had not publicly responded and no regulator has made findings.
So What?
Expect volatility in BLLN until management responds; any regulatory confirmation would hit diagnostics names reliant on Medicaid reimbursement.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.